Noted in the trend band, $SENS has floated within its average for the last 3 months, with a small upward move from its initial 180 day CGM submission to the FDA. Although $SENS has report net loss, it is expected from a company within its product growth cycle. Additionally, new employees were hired to speed the R & D of its programming and engineering. New Employees were paid in equity shares, and lockup is until milestones are achieved, which has contributed to its expenses.
So, whats next? The 180 CGM sensor is still in play as FDA has it on the table for review. Considering the extent of healthcare networks added to the market, another potential for $SENS is a merger or partnership from big pharma.
So, whats next? The 180 CGM sensor is still in play as FDA has it on the table for review. Considering the extent of healthcare networks added to the market, another potential for $SENS is a merger or partnership from big pharma.